<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We demonstrate the full counteracting ability of stable gastric pentadecapeptide BPC 157 against <z:chebi fb="0" ids="32588">KCl</z:chebi>-overdose (intraperitoneal (i), intragastric (ii), in vitro (iii)), NO-system related </plain></SENT>
<SENT sid="1" pm="."><plain>(i) We demonstrated potential (/kg) of: BPC 157 (10ng, 10μg ip, complete counteraction), l-arginine (100mg ip, attenuation) vs. L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (5mg ip, deadly aggravation), given alone and/or combined, before or after intraperitoneal <z:chebi fb="0" ids="32588">KCl</z:chebi>-solution application (9mEq/kg) </plain></SENT>
<SENT sid="2" pm="."><plain>Therapy was confronted with promptly unrelenting <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo> (&gt;12mmol/L), <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> (and <z:hpo ids='HP_0001324'>muscular weakness</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, low pressure in lower esophageal and pyloric sphincter) with an ultimate and a regularly inevitable lethal outcome within 30min </plain></SENT>
<SENT sid="3" pm="."><plain>Previously, we established BPC 157-NO-system interaction; now, a huge life-saving potential </plain></SENT>
<SENT sid="4" pm="."><plain>Given 30min before <z:chebi fb="0" ids="32588">KCl</z:chebi>, <z:hpo ids='HP_0000001'>all</z:hpo> BPC 157 regimens regained sinus rhythm, had less prolongation of QRS, and had no asystolic pause </plain></SENT>
<SENT sid="5" pm="."><plain>BPC 157 therapy, given 10min after <z:chebi fb="0" ids="32588">KCl</z:chebi>-application, starts the rescue within 5-10min, completely restoring <z:mpath ids='MPATH_458'>normal</z:mpath> sinus rhythm at 1h </plain></SENT>
<SENT sid="6" pm="."><plain>Likewise, other <z:hpo ids='HP_0002153'>hyperkalemia</z:hpo>-disturbances (<z:hpo ids='HP_0001324'>muscular weakness</z:hpo>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, low sphincteric pressure) were also counteracted </plain></SENT>
<SENT sid="7" pm="."><plain>Accordingly with NO-system relation, deadly aggravation by L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>: l-arginine brings the values to the control levels while BPC 157 always completely nullified lesions, markedly below those of controls </plain></SENT>
<SENT sid="8" pm="."><plain>Combined with l-arginine, BPC 157 exhibited no additive effect </plain></SENT>
<SENT sid="9" pm="."><plain>(ii) Intragastric <z:chebi fb="0" ids="32588">KCl</z:chebi>-solution application (27mEq/kg) - (<z:hpo ids='HP_0002153'>hyperkalemia</z:hpo> 7mmol/L): severe stomach mucosal lesions, sphincter failure and peaked T waves were fully counteracted by intragastric BPC 157 (10ng, 10μg) application, given 30min before or 10min after <z:chebi fb="0" ids="32588">KCl</z:chebi> </plain></SENT>
<SENT sid="10" pm="."><plain>(iii) </plain></SENT>
<SENT sid="11" pm="."><plain>In HEK293 cells, hyperkalemic conditions (18.6mM <z:chebi fb="120" ids="26216">potassium</z:chebi> concentrations), BPC 157 directly affects <z:chebi fb="120" ids="26216">potassium</z:chebi> conductance, counteracting the effect on membrane potential and depolarizations caused by hyperkalemic conditions </plain></SENT>
</text></document>